scholarly journals Evaluation of the efficacy of recombinant tissue plasminogen activators in improving clinical status of acute ischemic stroke: A randomized clinical trial in Iran

2018 ◽  
Vol 5 (9) ◽  
pp. 2697-2702
Author(s):  
Mojtaba Khazaei ◽  
Zaher Khazaei ◽  
Elham Goodarzi ◽  
Ali Ghadimi
Keyword(s):  
Clinical Trial ◽  
Ischemic Stroke ◽  
Treatment Group ◽  
Acute Ischemic Stroke ◽  
Clinical Status ◽  
Plasminogen Activators ◽  
Control Group ◽  
Tissue Plasminogen ◽  
The Mean ◽  
The Difference

Background: Acute ischemic stroke is caused by blockage of a cerebral artery and is also known as cerebrovascular accident (CVA). Recombinant tissue plasminogen activator (rt-PA) therapy is effective in reducing early and long-term neurologic disabilities if it is started quickly. Therefore, the aim of this study was to determine the efficacy of treatment with recombinant tissue plasminogen activators in improving the clinical status of acute ischemic stroke. Methods: The current study was performed as a clinical trial of two groups- treatment and control (n=20 per group). The treatment group consisted of patients who received rt-PA, while the control group consisted of patients who did not receive rt-PA. For each group, evaluation of neurological disabilities following ischemic stroke was based off the National Institutes of Health Stroke Scale (NIHSS), for early assessment of disability on the third day of treatment), and off the modified Rankin Scale (MRS) at 90 days after stroke. The drug effect criterion was used to reduce the neurological disability or the difference in NIHSS on day 3 after treatment. Also, the duration of onset of symptoms until the arrival of the patients to the emergency room (ER), as well as the risk factors, complications and number of deaths in both groups, were recorded. Data obtained were analyzed by SPSS software. Results: The results of the study showed that the mean of ER arrival time, NIHSS before treatment, and NIHSS on day 3 of treatment in the control group was higher than that of the treatment group; the difference was statistically significant (P<0.05). The results also indicated that the probability of improvement of neurological disabilities in the experimental group was greater than that of the control group (relative risk (RR) =1.25). Additionally, the odds ratio (OR) for receiving rt-PA in the NIHSS positive treatment group compared to the control group was equal to 1/5 (OR=1.5). The results showed that 30% of the patients in the treatment group were treated with a complication. The mean of MRS was higher in the control group at 90 days after the stroke, compared with the treatment group. Conclusion: Treatment with rt-PA reduces the neurological disability in patients with ischemic stroke, since the mean of MRS is lower in the treatment group, compared with the control group, after 90 days of treatment.

Abstract 2281: Full Dose IV-tPA Followed By IA Therapy For Acute Ischemic Stroke Does Not Increase Morbidity Or Mortality

Stroke ◽  
2012 ◽  
Vol 43 (suppl_1) ◽  
Author(s):  
Jeffrey M Katz ◽  
Calvin Natanzon ◽  
Avi Setton ◽  
Richard Libman
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Control Group ◽  
Bridging Therapy ◽  
Full Dose ◽  
Tissue Plasminogen ◽  
Symptomatic Intracranial Hemorrhage ◽  
The Mean ◽  
Iv Tpa

Background and Purpose: “Bridging Therapy” is well described in the literature. However the dose of bridging tissue plasminogen activator (tPA) is a matter of debate given the well-established guideline of 0.9 mg/kg as the standard intravenous dose. Previous and ongoing bridging trials use lower doses of IV-tPA (0.6 mg/kg) with a goal of maximizing safety. Our aim was to explore whether full bridging dose IV-tPA at 0.9 mg/kg can be given safely in combination with intra-arterial (IA)-tPA. Methods: Data were collected prospectively on 47 consecutive patients with acute ischemic stroke who were treated with endovascular stroke therapy (EST, that is IA-tPA +/- mechanical embolectomy (ME)). Patients who were candidates for IV-tPA, who did not clinically improve after receiving full dose IV-tPA (0.9mg/Kg), underwent EST (bridging group, n=23, 15/23 IA-tPA + ME). These patients were compared to patients treated with EST alone because they were not candidates for IV-tPA (control group, n=24, 14/24 IA-tPA + ME). Symptomatic intracranial hemorrhage (ICH) rates were recorded, as defined in the NINDS IV-tPA trial. Death rates were recorded at one month and modified Rankin score was used to measure functional outcome (6 month mean follow-up). Results: Mean age was 62 years in the bridging group and 63 years in the control group. Baseline mean National Institute of Health Stroke Scale was 20 in the bridging group and 21 in the control group (p = 0.188). The mean IA-tPA dose was 14.4 mg in the bridging group and 18.3 mg in the control group (p = 0.371). There was an 8% risk of symptomatic ICH in the control group and no symptomatic ICH in the bridging group (p = 0.155). At 30 days, mortality was 17% in the bridging group and 29% in the control group (p = 0.313). The mean follow-up modified Rankin score was 3 in the bridging group and 4 in the control group (p = 0.20). Conclusion: This non-randomized retrospective cohort study suggests that full dose IV-tPA combined with IA-tPA administered during EST is safe in patients with acute ischemic stroke. Given the possibility that full bridging dose tPA may be more effective than lower dose IV-tPA, a prospective, randomized bridging trial using full dose IV-tPA may be warranted.

Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction

2020 ◽  
Vol 38 (5) ◽  
pp. 385-393
Author(s):  
Jin-Xia Cao ◽  
Li Liu ◽  
Yun-Tao Sun ◽  
Qing-Hong Zeng ◽  
Zhen-Dong Yang ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Treatment Group ◽  
Endothelial Dysfunction ◽  
Acute Ischemic Stroke ◽  
Rating Scale ◽  
Mmse Score ◽  
Neurological Deficits ◽  
Control Group ◽  
Relative Safety ◽  
The Mean

Background: Escitalopram is one of the most commonly used SSRIs at present, which has the characteristics of quick onset, less interactions with other drugs, and relative safety. Objective: This study aims to investigate the effects of escitalopram on neural functional prognoses and endothelial dysfunction after acute ischemic stroke. Methods: One hundred eligible patients afflicted with acute ischemic stroke were randomized into two groups: control and treatment groups. Patients in the treatment group received escitalopram in addition to the basic therapies in the control group over a period of 90 days. Neurological deficits were quantified using the National Institutes of Health Stroke Scale (NIHSS) score and Barthel index (BI) score, cognitive impairment was determined using the Mini-Mental State Examination (MMSE) score, depressive symptoms were measured using the 17-item Hamilton Depression Rating Scale (HAMD). Furthermore, post-stroke depression (PSD) was defined based on the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), with a HAMD score ≥17. Flow-mediated vascular dilatation (FMD) of the brachial artery was use as a surrogate indicator for endothelial dysfunction assessment with ultrasound. Results: The mean NIHSS and HAMD scores on day 90 after treatment were significantly lower in the treatment group than in the control group (2.17±0.36 vs. 4.24±0.85; 5.81±1.35 vs. 10.43±4.91; P < 0.01), while the mean BI score and FMD were significantly higher in the treatment group (93.08±6.23 vs. 79.64±7.56, P < 0.01; 8.71±2.35 vs. 5.83±1.21, P < 0.05) than in the control group. The improvement in MMSE score was not significantly different between the two groups. Conclusions: Treatment with escitalopram early after ischemic stroke can improve neural functional prognoses and endothelial dysfunction. Escitalopram had less side effects, which is worthy of clinical prophylactic application.

Abstract WP336: Impact of Anti-Hypertensive Interventions for Treatment of Acute Ischemic Stroke in Patients Receiving Tissue Plasminogen Activator

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Jeffrey Leya ◽  
Elisabeth Donahey ◽  
Megan Rech
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Primary Endpoint ◽  
Univariate Analysis ◽  
Control Group ◽  
Poor Outcome ◽  
Tissue Plasminogen

Introduction: Early treatment of acute ischemic stroke (AIS) with recombinant tissue plasminogen activator (rtPA) within 4.5 hours of symptom onset is associated with neurologic improvement. A risk of rtPA is hemorrhagic conversion, which has a higher incidence in patients with elevated blood pressure at presentation. Current literature supports the use of blood pressure goals (<185/110 mm Hg) in patients qualifying for rtPA, but the effects of anti-hypertensive (anti-HTN) medications within the first 24 hours of AIS on outcomes has not been evaluated. Hypothesis: AIS patients requiring anti-HTN medications (anti-HTN group) before rtPA have a poorer outcome at 90 days compared to those that do not need anti-HTN medications (control group). Methods: This was a retrospective cohort study of patients >18 years diagnosed with AIS from January 2011 through December 2015 who received one or multiple anti-HTN medication(s) prior to rtPA administration, compared to control patients who did not. Primary endpoint was poor outcome at 90 days, defined as a modified Rankin Scale (mRS) of ≥3. Univariate analysis with Chi-square, Fisher’s exact test or t-test was performed. Multivariate analysis was conducted. Results: Of 235 patients evaluated for AIS, 145 (61.7%) were included. Baseline demographics were well matched, though more patients in the anti-HTN group had a history of HTN (86.7% vs. 62.5%, p<0.01), diabetes (33.3% vs. 17.5%, p=0.04) and chronic kidney disease (20% vs. 7.5%, p=0.04). There was no difference in the primary endpoint of poor outcome (mRS ≥3) between groups who received blood pressure medication versus those who did not (37% anti-HTN group vs. 30% control, p=.374). There was no difference in hemorrhagic conversion (13.3% anti-HTN group vs. 6.3% control, p=.187). Mortality at 90 days did not differ between groups (11% who received anti-HTN vs. 7.5%, p=.508). Conclusion: No difference was observed in poor outcomes, hemorrhagic conversion, or 90-day mortality in patients receiving anti-HTN medications prior to rtPA compared to those that did not. These results suggest that aggressive blood pressure management should be used to control hypertension in AIS who may qualify for rtPA, though larger, randomized trials are needed to confirm this finding.

Abstract 65: Effects of Immediate Blood Pressure Reduction on Two-Year Mortality and Major Disability in Patients With Acute Ischemic Stroke

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Jiang He ◽  
Yonghong Zhang ◽  
Tan Xu ◽  
Dali Wang ◽  
Chung-Shiuan Chen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Treatment Group ◽  
Acute Ischemic Stroke ◽  
Antihypertensive Treatment ◽  
Blood Pressure Reduction ◽  
Control Group ◽  
Antihypertensive Medications ◽  
Vascular Events

Although elevated blood pressure (BP) is very common in patients with acute ischemic stroke, the management of hypertension among them remains controversial. We tested the effect of immediate BP reduction on two-year mortality and major disability in acute ischemic stroke patients. The China Antihypertensive Trial in Acute Ischemic Stroke, a randomized, single-blind, blinded end-points trial, was conducted in 4,071 patients with ischemic stroke within 48 hours of onset and elevated systolic BP (SBP). Patients were randomly assigned to receive antihypertensive treatment (n=2,038) or to discontinue all antihypertensive medications (n=2,033) during hospitalization. Post-treatment follow-ups were conducted at 3, 12, and 24 months after hospital discharge. The primary outcome was a composite of death and major disability at the two-year follow-up visit. Mean SBP was reduced by 21.8 in the treatment group and 12.7 mm Hg in the control group within 24 hours after randomization (P<0.001). Mean SBP was 137.3 mm Hg in the treatment group and 146.5 in the control group at day 7 after randomization (P<0.001). At two-year follow-up, study outcomes were obtained in 1945 (95.4%) participants in the treatment group and 1925 (94.7%) in the control group. 78.8% of the patients in the treatment group and 72.6% in the control group reported the use of antihypertensive medications (p<0.001). SBP was 138.8 mmHg in the antihypertensive treatment group and 139.7 in the control group (p=0.02). Among patients in the antihypertensive treatment group, 24.5% (476/1945) died or had a major disability, compared with 22.1% (425/1925) in the control group (odds ratio 1.14 [95% CI 0.99 to 1.33], p=0.078). Hazard ratios for all-cause mortality (1.01 [0.81, 1.25], p=0.95), recurrent stroke (0.91 [0.73, 1.13], p=0.40), and vascular events (0.97 [0.79, 1.19], p=0.76) were not statistically significant comparing the antihypertensive treatment group to the control group. The effect of antihypertensive treatment did not differ by pre-defined subgroups. In conclusion, among patients with acute ischemic stroke, BP reduction with antihypertensive medications during hospitalization did not reduce or increase the composite outcome of death and major disability over two years.

scholarly journals PENTOXIFYLLINE IN ACUTE ISCHEMIC STROKE PATIENTS WITH BLOOD HYPERVISCOSITY

2018 ◽  
Vol 10 (1) ◽  
pp. 307 ◽  
Author(s):  
Al Rasyid ◽  
Salim Harris ◽  
Eny Nurhayat ◽  
Joedo Prihartono
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Blood Viscosity ◽  
Control Treatment ◽  
Control Group ◽  
Study Group ◽  
Control Groups ◽  
Stroke Treatment ◽  
Patient Series ◽  
The Difference

Objective: This study evaluated the efficacy of pentoxifylline, a hemorrheologic agent, for treating acute ischemic stroke in patients with bloodhyperviscosity.Methods: Patients were randomly allocated within 3 days of stroke onset to study or control treatment. All the patients received the standard acuteischemic stroke treatment. The study treatment was intravenous pentoxifylline 1200 mg/day for 5 consecutive days and oral pentoxifylline 800 mgin two divided doses for 23 days. Blood viscosity was evaluated on days 7 and 30. The outcomes were assessed by the National Institutes of HealthStroke Scale (NIHSS), modified Rankin Scale, and Barthel index (BI) criteria.Results: The median baseline viscosity was 6.89 poise in the study and 6.46 poise in the control groups and had decreased in all the patients ondays 7 and 30. The decrease in the study group on day 7 (1.13 poise) was greater than that in the control group (0.57 poise); the difference was notsignificant. The NIHSS score improved by 32% in the study group (relative risk [RR]=1.00, 95% confidence interval [CI]: 0.421–3.556; p=1.00). At1-month, 67% of the study group had a good functional outcome (RR=1.026, 95% CI: 0.656–1.605; p=0.909).Conclusion: Pentoxifylline decreased blood viscosity and improved clinical outcome in this patient series.

scholarly journals Mecobalamin and early functional outcomes of ischemic stroke patients with H-type hypertension

2018 ◽  
Vol 64 (5) ◽  
pp. 428-432
Author(s):  
Meixia Yuan ◽  
Beiyun Wang ◽  
Shijin Tan
Keyword(s):  
Ischemic Stroke ◽  
Treatment Group ◽  
Carotid Artery ◽  
Conventional Therapy ◽  
Functional Outcomes ◽  
Inflammatory Factors ◽  
Control Group ◽  
Serum Homocysteine ◽  
The Difference ◽  
Hs Crp

SUMMARY OBJECTIVE To analyze the effect of mecobalamin on the early-functional outcomes of patients with ischemic stroke and H-type hypertension. METHODS From October of 2014 to October of 2016, 224 cases of ischemic stroke and H-type hypertension were selected. The patients were randomly divided into treatment control groups, with 112 patients in each group. The control group was treated with the conventional therapy. The observation group was treated with 500 µg of mecobalamin three times a day in addition to the conventional therapy. We compared serum homocysteine (Hcy), hs-CRP levels, carotid plaques, and NIHSS scores between the two groups on the 2nd day and at 4 weeks, 8 weeks, 3 months, and 6 months. RESULTS After 4 weeks, 8 weeks, 3 months and 6 months, the difference of serum Hcy level between the two groups was statistically significant (t = 4.049, 3.896, 6.052, 6.159, respectively. All P <0.05). After the treatment, at 4 weeks, 8 weeks, 3 months and 6 months, the levels of hs-CRP in the treatment group were significantly lower than those in the control group (t = 37.249, 28.376, 26.454, 20.522, respectively. All P <0.01). After 3 months and 6 months, the carotid artery plaques were significantly reduced in the treatment group compared to those in the control group (t = 2.309 and 2.434. All P <0.05). After 3 months and 6 months, the NIHSS score was significantly higher in the treatment group compared to those in the control group (t = 2.455 and 2.193. All P <0.05). CONCLUSION Mecobalamin can reduce the level of plasma homocysteine, then lead to reductions of levels of plasma inflammatory factors and volume of carotid artery plaques, resulting in more significant functional recovery.

scholarly journals The Early Outcomes of Nurse Case Management in Patients with Acute Ischemic Stroke Treated with Intravenous Recombinant Tissue Plasminogen Activator: A Prospective Randomized Controlled Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Urai Kummarg ◽  
Siriorn Sindhu ◽  
Sombat Muengtaweepongsa
Keyword(s):  
Ischemic Stroke ◽  
Case Management ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Fast Track ◽  
Recombinant Tissue Plasminogen Activator ◽  
Control Group ◽  
Nurse Case Management ◽  
Tissue Plasminogen

Background. Intravenous recombinant tissue plasminogen activator (i.v. rt-PA) is the milestone treatment for patients with acute ischemic stroke. Stroke Fast Track (SFT) facilitates time reduction, guarantees safety, and promotes good clinical outcomes in i.v. rt-PA treatment. Nursing case management is a healthcare service providing clinical benefits in many specific diseases. The knowledge about the efficacy of a nurse case management for Stroke Fast Track is limited. We aim to study the effect of nurse case management on clinical outcomes in patients with acute ischemic stroke involving intravenous recombinant tissue plasminogen activator (i.v. rt-PA) treatment. Methods. Seventy-six patients with acute ischemic stroke who received i.v. rt-PA treatment under Stroke Fast Track protocol of Thammasat University Hospital were randomized into two groups. One group was assigned to get standard care (control) while another group was assigned to get standard care under a nurse case management. The National Institute of Health Stroke Scale (NIHSS) at 24 hours after treatment between the control and the experimental groups was evaluated. Results. Time from triage to treatment in the experimental group was significantly faster than in the control group (mean = 39.02 and 59.37 minutes, respectively; p=.001). The NIHSS at 24 hours after treatment in the nurse case management group was significantly improved as compared to the control group (p=.001). No symptomatic intracranial hemorrhage (sICH) was detected at 24 hours after onset in both groups. Conclusion. The nurse case management should provide some benefits in the acute stroke system. Although the early benefit is demonstrated in our study, further studies are needed to ensure the long-term benefit and confirm its profit in patients with acute ischemic stroke.

Using PRODIGY to Increase School Motivation Among Malaysian Children: A Study in a Rural Primary School in Perak

2015 ◽  
Vol 1 ◽  
Author(s):  
Aslina Ahmad
Keyword(s):  
Treatment Group ◽  
Rural Areas ◽  
Extrinsic Motivation ◽  
Descriptive Analysis ◽  
Control Group ◽  
Counseling Skills ◽  
Intrinsic And Extrinsic Motivation ◽  
The Mean ◽  
Motivation Scale ◽  
The Difference

This study evaluates the effect of a school programme called PRODIGY that uses counseling skills to motivate students in rural areas in Perak, Malaysia. A total of 78 students (N = 78), who were 12 years of age participated in this study. The effect of the programme was measured by comparing the difference between mean scores of the pretest and the posttest. The instruments used to measure school motivation were (a) Elementary School Motivation Scale by Guay, Marsh, Dowson and Larose (2005) and (b) Intrinsic and Extrinsic Motivation by Harter (1981). Descriptive analysis was used to find the difference in mean scores and the standard deviation of the data. Results show that the mean score among students from the treatment group was higher compared to the control group. Teachers commented that children in the treatment group were more confident and took the initiative to meet with teachers whenever they have difficulties in their studies.

scholarly journals PROFIL PASIEN STROKE ISKEMIK AKUT DENGAN TERAPI RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR DI RSUP DR. KARIADI SEMARANG

2020 ◽  
Vol 36 (4) ◽  
Author(s):  
Retnaningsih Retnaningsih ◽  
Theodorus Kevin Hendartono
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Barthel Index ◽  
Recombinant Tissue Plasminogen Activator ◽  
Stroke Patients ◽  
Tissue Plasminogen ◽  
The Mean ◽  
Age Range

 PROFILE OF ACUTE ISCHEMIC STROKE PATIENTS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR THERAPY IN DR. KARIADI HOSPITAL SEMARANGABSTRACTIntroduction: The use of recombinant tissue plasminogen activator (rtPA) is recommended within 4.5 hours from onset, with door to needle (DTN) time <60 minutes, so that it will decrease morbidity and mortality rates.Aims: To evaluate the evaluate the profile of acute ischemic stroke patients with rtPA therapy in Dr. Kariadi Hospital Semarang.Methods: This was a descriptive study by looking at medical records of patients with acute ischemic stroke with onset less than 4.5 hours performed rtPA therapy in Dr. Kariadi Hospital Semarang during Januari 2017 until May 2018.Results: There were 36 patients, 19 (52.8%) male, 17 (47.2%) female. Age range from 36 to 74 years with stroke onset 15-180 minutes. There were lacuner ischemia in 29 patients (80.6%) and teritorial ischemia in 7 patients (19.4%). The mean DTN time 67.22 ± 12.29 with DTN time for rtPA >60 minutes was performed in 23 (63.9%) patients and <60 minutes in 13 (36.1%) patients. The mean NIHSS on admission 8.67±3.51; The mean NIHSS within first 24 hours 6.94±3.25; The mean NIHSS on discharge 5.64±5.50. The mean Barthel Index on admission 57.97±19.27, and The mean Barthel Index on discharge 73.33±26.25.Discussion: There was an improvement of NIHSS and Barthel Index in acute ischemic stroke patients with rtPA therapy. The mean DTN time still >60 minutes, so that service system improvements are needed in order to improve clinical outcomes of acute ischemic stroke patients with rtPA therapy (DTN time <60 minutes).Keywords: Barthel Index, NIHSS, recombinant tissue plasminogen activator (rtPA), ischemic stroke, door to needle (DTN)ABSTRAKPendahuluan: Pemberian recombinant tissue plasminogen activator (rtPA) direkomendasikan dalam waktu sampai 4,5 jam dengan waktu door to needle (DTN) <60 menit agar dapat menurunkan tingkat morbiditas dan mortalitas pada stroke iskemik akut.Tujuan: Untuk mengetahui profil pasien stroke iskemik akut dengan terapi rtPA di RSUP Dr. Kariadi Semarang.Metode: Penelitian deskriptif dengan melihat rekam medis pasien-pasien stroke iskemik akut periode Januari 2017 hingga Mei 2018 dengan onset kurang dari 4,5 jam yang mendapatkan terapi rtPA di RSUP Dr. Kariadi Semarang.Hasil: Dari 36 subjek, didapatkan proporsi laki-laki lebih banyak dari pada perempuan (52,8% vs 47,2%) dan rerata usia 58±8,63 tahun. Rerata waktu awitan adalah 92,5±42,79 menit dengan tipe iskemik lakuner (80,6%) dan rerata waktu DTN 67,22±12,29 menit.  Rerata NIHSS 24 jam pertama adalah 6,94±3,25 yang menurun menjadi 5,64±5,50 saat keluar RS. Rerata Indeks Barthel subjek saat masuk RS adalah 57,91±19,27 yang meningkat saat keluar menjadi 73,33±26,25.Diskusi: Terdapat perbaikan nilai NIHSS dan Indeks Barthel pada subjek stroke iskemik akut yang mendapatkan terapi rtPA. Rerata waktu DTN adalah >60 menit, menunjukkan perlunya perbaikan sistem pelayanan untuk meningkatkan luaran klinis pasien stroke iskemik akut dengan DTN <60 menit.Kata kunci: Door to needle, Indeks Barthel, NIHSS, recombinant tissue plasminogen activator, stroke iskemik  

scholarly journals The Beneficial Effects of Moxibustion on Overweight Adolescent Girls

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Yuan-Chieh Yeh ◽  
Chin-Chang Chen ◽  
Ching-Yi Cheng ◽  
Hsin-Ning Chang ◽  
Tse-Hung Huang
Keyword(s):  
Treatment Group ◽  
Adolescent Girls ◽  
Controlled Trial ◽  
Control Group ◽  
Psychological Benefits ◽  
Beneficial Effects ◽  
Overweight Adolescent ◽  
The Mean ◽  
The Difference ◽  
Overweight Adolescent Girls

Among adolescent girls, overweight or obesity has both physical and psychological involvement. We conducted a randomized controlled trial of moxibustion using a moxa burner. Fifty-four eligible girls aged 15–18 years with a body mass index (BMI) greater than 25.3 were enrolled in the study. The girls were randomly allocated to the treatment (n = 27) and control (n = 27) groups. The girls underwent treatment three times per week for 8 weeks (24 treatments). Moxibustion was applied to the RN12, RN6, ST25, ST36, and SP6 acupoints. Physical assessments were BMI, waist-to-hip ratio (WHR), and body fat ratio (BFR). Psychological outcomes were measured using the Rosenberg Self-Esteem Scale (RSE). Data were collected at the beginning of the study (baseline), week 4, and week 8. Of the 54 participants, 46 completed the trial. The difference in mean BMI from baseline between the two groups was 0.097 ( p = 0.655 ) at week 4 and −0.794 ( p = 0.001 ) at week 8. The mean WHR of the treatment group was significantly reduced compared with baseline, with a −0.011 ( p = 0.017 ) and −0.035 ( p < 0.001 ) mean change at weeks 4 and 8, respectively. The mean BFR was slightly reduced (−0.253; p = 0.474 ) at week 4 compared with baseline in the treatment group. At week 8, it was significantly reduced (−2.068; p < 0.001 ) from baseline in the treatment group. The mean RSE in the treatment group showed no significant increase from baseline at week 4 (0.155 points, p = 0.803 ), but it improved significantly from baseline at week 8 (1.606 points, p = 0.021 ) compared to that in the control group. No obvious adverse effect was reported during this study. Moxibustion using a moxa burner may be an effective and safe intervention for overweight adolescent girls, having both physical and psychological benefits.

Sign in / Sign up

Export Citation Format

Share Document